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Abstract. This article describes the protocol for the Systematic Multi-domain Alzheimer’s Risk Reduction Trial (SMARRT),
a single-blind randomized pilot trial to test a personalized, pragmatic, multi-domain Alzheimer’s disease (AD) risk reduction
intervention in a US integrated healthcare delivery system. Study participants will be 200 higher-risk older adults (age 70–89
years with subjective cognitive complaints, low normal performance on cognitive screen, and ≥ two modifiable risk factors
targeted by our intervention) who will be recruited from selected primary care clinics of Kaiser Permanente Washington,
oversampling people with non-white race or Hispanic ethnicity. Study participants will be randomly assigned to a two-year
Alzheimer’s risk reduction intervention (SMARRT) or a Health Education (HE) control. Randomization will be stratified by
clinic, race/ethnicity (non-Hispanic white versus non-white or Hispanic), and age (70–79, 80–89). Participants randomized
to the SMARRT group will work with a behavioral coach and nurse to develop a personalized plan related to their risk factors
(poorly controlled hypertension, diabetes with evidence of hyper or hypoglycemia, depressive symptoms, poor sleep quality,
contraindicated medications, physical inactivity, low cognitive stimulation, social isolation, poor diet, smoking). Participants
in the HE control group will be mailed general health education information about these risk factors for AD. The primary
outcome is two-year cognitive change on a cognitive test composite score. Secondary outcomes include: 1) improvement
in targeted risk factors, 2) individual cognitive domain composite scores, 3) physical performance, 4) functional ability, 5)
quality of life, and 6) incidence of mild cognitive impairment, AD, and dementia. Primary and secondary outcomes will be
assessed in both groups at baseline and 6, 12, 18, and 24 months.
Keywords: Alzheimer’s disease, dementia, health promotion, integrated delivery of health care, risk reduction behavior
INTRODUCTION
Alzheimer’s disease (AD) prevalence is growing,
creating a critical need for prevention. The num-
ber of people worldwide living with AD and related
dementias is expected to rise from 47 million in
2015 to 132 million by 2050 [1]. Current medications
∗Correspondence to: Kristine Yaffe, MD, Professor of Psychi-
atry, Neurology and Epidemiology, 4150 Clement Street, 181G,
San Francisco, CA 94121, USA. Tel.: +1 415 221 4810; E-mail:
Kristine.yaffe@ucsf.edu.
do not change the disease course [2], and several
drugs have recently failed Phase III trials [3–10];
thus, there is growing interest in strategies to pre-
vent AD [11, 12]. We have estimated that up to 30%
of AD may be attributable to modifiable risk factors
including physical inactivity, low education, smok-
ing, diabetes, hypertension, depression, and obesity
[13, 14]. Our estimates are now being supported by
several large population-based cohort studies, which
are finding that in some populations AD prevalence is
decreasing in parallel with population-level changes
in risk factors, such as better education, lower smok-
ing, and better control of cardiovascular risk factors
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[15–21]. In addition, multi-domain prevention trials
in Europe and Asia have found that interventions tar-
geting multiple risk factors simultaneously in older
adults can slow cognitive decline and reduce cogni-
tive impairment [22–24], although results have been
mixed [25–27]. These studies raise hope that multi-
domain risk reduction interventions in higher-risk
older adults have the potential to delay the onset of
AD; however, additional studies are needed to clar-
ify the effects of different intervention approaches in
different study populations.
To date, there has not been a multi-domain
Alzheimer’s risk reduction trial in the US. In addi-
tion, multi-domain risk reduction trials to date have
typically involved relatively intensive interventions
that would be difficult to implement in real-world
settings. The Systematic Multi-domain Alzheimer’s
Risk Reduction Trial (SMARRT) is a single-blind
randomized pilot trial to test a personalized, prag-
matic, multi-domain AD risk reduction intervention
in a US integrated healthcare delivery system. The
purpose of the pilot trial is to lay the foundation
for a future multisite trial by developing and test-
ing procedures and demonstrating proof-of-concept.
This manuscript describes the study protocol for
SMARRT.
MATERIALS AND METHODS
Study objectives
Primary objective
The primary objective of this pilot trial is to collect
preliminary data on SMARRT compared to Health
Education (HE) control. This will provide us with
proof-of-concept data for our primary outcome of
two-year cognitive change and will enable us to
estimate effect sizes for a larger multi-site trial. In
addition, it will enable us to assess feasibility and
acceptability and to determine whether intervention
refinements are needed.
Secondary objectives
Our secondary objectives are to compare changes
in Alzheimer’s risk factors over two years in those
randomized to SMARRT versus HE. The results will
determine if SMARRT can have a meaningful impact
on cognition by demonstrating significantly greater
risk factor change than HE.
In addition, we will gather preliminary data on
the impact of SMARRT versus HE on cognitive
domain scores, physical performance, functional
ability, quality of life, and incidence of mild cognitive
impairment (MCI) and AD.
Overview of study design
This study involves a pragmatic, single-blind, ran-
domized controlled pilot trial. We will randomize 200
higher-risk older adults to the two-year SMARRT
intervention or HE control. For the intervention, the
team will work with participants to develop a tai-
lored action plan to address risk reduction. Targeted
areas will include: increasing physical, mental, and
social activities; optimally controlling cardiovascu-
lar risk factors (hypertension, diabetes), including
avoiding both hyper and hypoglycemia among people
with diabetes; quitting smoking; reducing depres-
sive symptoms; improving sleep; neuroprotective
diet; and decreasing use of potentially harmful
medications. The HE group will received general
information about these AD risk factors. Primary and
secondary outcomes will be assessed in both groups
at baseline and 6, 12, 18, and 24 months. The study
flow diagram is provided in (Fig. 1), and an overview
of study procedures is provided in Table 1.
Setting
Kaiser Permanente Washington (KPWA) is an inte-
grated healthcare delivery system with about 710,000
members in the Northwest United States that pro-
vides members with both insurance coverage and
healthcare. Because KPWA provides insurance cov-
erage, we have complete information about members’
healthcare utilization as well as diagnosis and proce-
dure codes and medication fills. About two-thirds of
KPWA members receive all or nearly all clinical care
from KPWA physicians at KPWA-owned clinics. For
those members we also have information on clinical
measures such as vital signs (e.g., blood pressure val-
ues) and laboratory test results. This study will only
recruit members who are receiving their clinical care
within KPWA’s healthcare system. The University of
California, San Francisco (UCSF) will provide study
oversight.
Regulatory review and approval
All study procedures have been reviewed and
approved by Institutional Review Boards (IRBs) at
KPWA and UCSF, and the study will be registered
on ClinicalTrials.gov. All study participants will pro-
vide written, informed consent before participating in
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Fig. 1. Systematic Multi-domain Alzheimer’s Risk Reduction Trial (SMARRT) Study Flow.
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Table 1
Overview of study procedures
Procedure Screening Baseline Health coach Health 6 Month 12 Month 18 Month 24 Month
Sessions education Assessment Assessment Assessment Assessment
(SMARRT (HE Control
Group Only) Only)
Inclusion/Exclusion Criteria X
Informed Consent Form X X (1st session)
Actigraph X X X X X
Physical Function Tests X X X X X
Blood Pressure and Height/Weight X X X X X
Questionnaire packet X X X X X
Neuropsychological Test Battery X X X X X
Meet with Interventionist X
Mailed Education Forms X
Adverse Events X X X X X X X
assessments or intervention activities. We received
a consent and Health Insurance Portability and
Accountability Act (HIPAA) waiver to use electronic
health records (EHR) to identify and recruit potential
participants. HIPAA is a national privacy regulation
in the US that requires all research study participants
to review and sign a form that describes what type
of information is being collected and how it will be
used prior to participating in a study. IRBs can pro-
vide researchers with permission to use patient data
for research without their prior approval when certain
conditions are met, such as the research involves no
more than minimal risk and is of sufficient importance
to outweigh intrusion into the privacy of research
subjects. Consistent with federal and state laws, all
KPWA patients are provided with a Notice of Privacy
Practices stating that their information may be used
for research. Patients who have previously requested
not to be contacted or have their records reviewed for
research studies will be excluded.
Inclusion/exclusion criteria
Inclusion criteria
Participants must meet all the inclusion criteria
to participate in this study. These are: age 70–89
years (to target a population at increased risk of
experiencing cognitive decline that is still able to
participate fully in a two-year intervention study);
English language fluency; cognitive concern (self-
reported decline in memory or thinking over past 2
years); low normal performance on a brief telephone
cognitive screen (short Cognitive Abilities Screening
Instruments [CASI] [28]); and at least two additional
risk factors that will be targeted by our intervention
(Table 2). Low normal CASI scores will be defined
as 26 to 29 inclusive. This reflects scores lower than
the median score of participants enrolled in the Adult
Changes in Thought (ACT) [29] Study (median 30,
range 6 to 33) while excluding those whose scores
suggest possible dementia (score ≤25) [28, 30]. A
novel feature of this study is that for recruitment, we
will identify many of these risk factors using EHR
data. We will use the EHR data to target recruitment to
people with at least one risk factor of interest, which
should improve efficiency of recruitment. For most
of these risk factors, we will confirm them during
telephone screening, and these data will be used to
determine final study eligibility.
Exclusion criteria
Candidates meeting any of the exclusion criteria
during EHR review or telephone screening will be
excluded from study participation. For initial deter-
mination of eligibility, we will rely on information
recorded in the EHR, such as International Classifi-
cation of Diseases 10 (ICD-10) diagnosis codes and
medication fills. We will exclude those who are cur-
rently residing in a skilled nursing or rehabilitation
facility; received palliative care or hospice services
(based on clinic encounters, past 2 years); Charl-
son comorbidity index score >5 (based on ICD-10
diagnoses, past year, to exclude severe comorbid-
ity likely to interfere with ability to participate in
the study) [31]; bipolar illness or schizophrenia (any
ICD-10 code, past 2 years, or receiving two or more
fills for antipsychotic medications, past 6 months);
current alcohol or drug use disorder (any ICD-10
code, past 2 years); receiving chronic opioid ther-
apy (enough supplied to have taken 20 morphine
equivalent doses/day for ≥70 days in the previous
90-day period); Parkinson’s disease, amyotrophic lat-
eral sclerosis, or multiple sclerosis (any ICD-10,
past 2 years); severe visual impairment (any ICD-10,
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Table 2
Inclusion criteria for SMARRT Trial
Inclusion Criteria Definition Data source
Older age 70–89 years EHR
Language Fluent in English EHR and telephone
screening
KPWA enrollment status ≥12 months (allow 3-month gap) EHR
Low-normal cognitive
performance
Brief CASI [28] score 26 to 29 inclusive Telephone screening
Subjective cognitive
complaints
Self-report of concern with memory or thinking, as captured by
replying yes to the question: “In the past two years, have you
experienced a decline in your memory or thinking?”
Telephone screening
≥2 targeted risk factors
• Poorly controlled
hypertension
Systolic blood pressure ≥140 and/or diastolic blood pressure
≥90 twice in the past 6 months
EHR
• Poorly controlled
diabetes, with evidence
Hyperglycemia: ≥1 hemoglobin A1c (HbA1c) ≥8.0 in past
12 months
EHR
of either hyperglycemia
or potential
hypoglycemia
Potential hypoglycemia: Diabetes, taking insulin (at least one fill in
past 6 months) and one or more of the following: 1) most recent
HbA1c in past 12 months ≤6.0; 2) diagnosis code for
hypoglycemia in past 1 year
• High depressive
symptoms
Initial recruitment: Score ≥3 on Patient Health Questionaire-2
(PHQ-2) [50] screen in past 12 months
EHR (recruitment)
Final eligibility: Score ≥10 on PHQ-8 [51] Telephone screening
(final eligibility)
• Poor sleep Initial recruitment: diagnosis code for sleep disorder and/or ≥2 fills
for a sleep medication in the past 12 months
EHR (recruitment)
Final eligibility: Scoring above the cut-off on the sleep
questionnaire (problems with sleep 3+ nights/week and bothered
“somewhat” or more)
Telephone screening
(final eligibility)
• Risky medications ≥2 fills for medications in a given class of risky medications in the
past 6 months, per modified Beers criteria [48]
EHR
• Physical inactivity <30 minutes moderate intensity most days (<150 minutes/week,
Surgeon General guidelines)
Telephone screening
• Social isolation Rarely or never get social and emotional support needed (scoring
≥6 out of 9 possible points) [36]
Telephone screening
• Current smoking Recruitment: EHR evidence of current use of any tobacco EHR (recruitment)
Final eligibility: self-reported current smoking on telephone screen Telephone screening
(final eligibility)
past 2 years, which could limit ability to partici-
pate in the intervention and outcomes assessments);
requested not to be contacted or not to have their
medical record reviewed for research studies (KPWA
Health Research Institute database); and evidence of
dementia (ICD-10 codes, past 2 years, or prescrip-
tion fills for dementia medications such as donepezil
or memantine, past 2 years). The use of EHR data
to identify exclusion criteria also is a novel feature
that is designed to improve efficiency of recruitment.
Additional exclusion criteria will be assessed during
telephone screening and will include: severe hearing
impairment (unable to complete telephone screen);
inability to come in for assessments; inability to par-
ticipate in an intervention and outcomes assessments
conducted in English; plans to disenroll from KPWA
or move out of the area in the next 2 years; cur-
rent enrollment in the Adult Changes in Thought
(ACT) study; answering ‘yes’ to the question “have
memory problems contributed to a decline in your
ability to care for yourself over the past year;” answer-
ing ‘no’ to the question “has your memory or thinking
declined in the past 2 years;” short CASI scores ≤25
(suggestive of cognitive impairment) or ≥30 (low
likelihood of experiencing cognitive decline over 2
years); or inability to provide informed consent.
Enrollment and assessment procedures
Recruitment
Our goal is to target higher-risk individuals who
will be motivated to make medical and behavioral
changes to reduce their Alzheimer’s risk. Initial eli-
gibility will be determined using medical risk data
from the EHR. Final eligibility will be determined
during telephone screening.
Initial eligibility criteria using EHR data will be
based on having at least one targeted risk factor. We
will recruit among those with at least one targeted risk
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factor (rather than two) because not all risk factors of
interest can be identified from the EHR (e.g., physi-
cal activity), and we expect many individuals initially
identified as having one risk factor will ultimately
have two or more based on information collected on
the telephone interview. The final inclusion criteria
of at least two risk factors will be determined via
a combination of EHR data (for hypertension, dia-
betes, and contraindicated medications) and phone
screening (for the remaining risk factors). In order to
achieve greater diversity, we will use race-ethnicity
information from KPWA demographic files to over-
sample potential participants who are Hispanic or
non-white, with a goal of having at least 30% of study
participants from diverse backgrounds.
Recruitment letters describing the study will be
mailed to current KPWA members who meet initial
eligibility criteria. These letters will include a phone
number that participants can call to opt out of being
contacted for this study.
Telephone screening evaluation
Approximately one week after letters have been
mailed, interviewers will call potentially eligible peo-
ple and describe the study activities, randomization,
and risks and benefits of the study. They will confirm
understanding, invite questions, and obtain verbal
informed consent to continue with the screening pro-
cess. Final eligibility will be determined using a
standardized screening questionnaire.
Because our goal is to enroll people with low nor-
mal cognitive function, we will also perform the short
telephone version of the CASI [28]. Enrollment will
be restricted to those whose scores fall between 26
and 29 inclusive (see inclusion criteria section for
rationale). Individuals who are eligible and inter-
ested will then be scheduled for in-person written
consent and baseline assessment, and will be sent an
accelerometer by mail to obtain a measure of baseline
levels of physical activity.
Consenting procedure
At the written consent and baseline assessment
visit, the assessor will discuss the nature of the
study and review the consent and HIPAA authoriza-
tion form. All study participants will provide written
informed consent.
Baseline assessments
All participants will complete the assessments
listed below at baseline and four follow-up visits
spaced over 24 months (approximately 6, 12, 18,
and 24 months).
Primary outcome: Two-year cognitive change
(composite score)
Cognitive function will be measured by a global
composite score from the modified Neuropsycholog-
ical Test Battery (mNTB) [23, 32], a comprehensive
battery including tests of memory (Wechsler Memory
Scale-Revised [WMS-R] Visual Paired Associates,
WMS-R Logical Memory, Consortium to Establish
a Registry for Alzheimer’s Disease [CERAD] Word
List); attention (WMS-R Digit Span); executive func-
tioning/processing speed (Trail Making Test, Stroop
Test, Digit Symbol Substitution Test); and language
(Category Fluency Test, Phonemic Fluency [FAS]).
The original NTB [33], on which the mNTB builds,
is well-validated with strong test-retest reliability
[33, 34], ability to distinguish between individuals
at different clinical stages (i.e., normal cognition,
MCI, AD) [34], and sensitivity to detecting cognitive
change in early stages of AD [33]. The mNTB [23,
32] improves on the original NTB by adding mea-
sures of executive functioning and processing speed,
domains that are important to assess in prevention
trials as these abilities are compromised by impor-
tant AD risk factors such as cardiovascular disease
and physical inactivity. Importantly, the mNTB was
found to be sensitive to change in prior multi-domain
AD risk reduction trials [23, 24].
Secondary outcomes
a) Improvement on Alzheimer’s risk factors.
Because this is a pilot study, one of our goals is
to quantify the number and type of Alzheimer’s
risk factors each person has at baseline as well
as change in each risk factor over two years
in response to the SMARRT intervention. This
will be accomplished using a combination of
validated objective and self-report measures as
well as EHR data. We chose to use individ-
ual measures rather than an AD risk score so
that we could examine each risk factor indepen-
dently. In addition, current AD risk scores do
not include all of the risk factors being targeted
in this study. Specific measures include:
• Self-reported physical activity (Rapid
Assessment of Physical Activity for Older
Adults, RAPA) [35]: a 9-item physical
activity inventory with yes/no responses,
designed for older adults and based on U.S.
Centers for Disease Control and Preven-
tion physical activity recommendations.
• Objectively measured physical activity
(waist-worn ActiGraph accelerometer):
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worn for 7 days prior to each assessment
visit with counts per minute aggregated
using ActiLife software.
• Leisure/Social Activity (PROMIS Satis-
faction with Participation in Discretionary
Social Activities, Short Form) [36]: 7-
item questionnaire that asks individuals
to rate satisfaction with engagement in
social and other leisure activities and social
connectedness in the past 7 days on a
5-point Likert scale (not at all . . . very
much).
• Cognitive activity (Cognitive Activity
Questionnaire) [37]: 11-item question-
naire that asks how often individuals
engage in cognitively stimulating activities
such as reading the newspaper or computer
activities on a 6-point Likert scale (once a
month/never . . . every day).
• Control of cardiovascular risk factors
(hypertension and diabetes): blood pres-
sure and Hemoglobin A1c (HbA1c) values
from EHR; height, weight, and blood pres-
sure measured at each assessment visit.
• Smoking: self-reported current tobacco
usage assessed by asking “Have you
smoked even a puff in the last 7 days?”
and if yes, “How many cigarettes have you
smoked in the last 7 days?”
• Diet (MIND diet score) [38, 39]: 15-item
questionnaire that assesses frequency of
consumption of specific food types (e.g.,
green leafy vegetables, red meat) over the
past 6 months.
• Depressive symptoms (Center for Epi-
demiologic Studies – Depression Scale,
CES-D) [40]: 20-item questionnaire that
assesses both positive and negative affect
over the last week rated on a scale from 0
(rarely or none of the time) to 4 (most or
all of the time).
• Sleep quality (Pittsburgh Sleep Quality
Index, PSQI) [41]: 19-item questionnaire
that assesses sleep quality and disturbances
over the past month (not at all, less than
once a week, once or twice a week, three
or more times a week).
• Potentially harmful medications (identi-
fied from KPWA pharmacy database):
based on a detailed list of contraindicated
medications developed for the intervention
(see Intervention section below).
b) Individual cognitive domain scores
c) Physical performance (Short Physical Perfor-
mance Battery, SPPB) [42]: Includes standard
tests of balance, time to complete five chair
stands, and usual gait speed.
d) Functional ability (Cognitive Function Instru-
ment, CFI) [43]: 14-item self-report inventory
of cognitive and functional difficulties in every-
day tasks (e.g., remembering appointments,
managing finances, driving).
e) Quality of life (PROMIS Global Health) [44]:
10-item questionnaire includes items on self-
rated health (physical, mental, social) as well
as pain and fatigue.
f) Incidence of MCI, dementia and AD (deter-
mined based on decline in cognitive status
through consensus conferences using standard
clinical criteria) [45–47].
Randomization and blinding
After the baseline visit, study participants will be
randomized in a 1:1 ratio to intervention and control
groups. Randomization will be implemented using
randomly permuted blocks of size two, stratified on
clinic, age (70–79 versus 80–89), and race/ethnicity
(non-Hispanic white versus non-white or Hispanic)
This will maximize blinding of outcome assessors by
ensuring that the sequence is not easy to guess and
will achieve balanced groups that accurately reflect
the underlying composition of the study population.
The randomization sequences will be generated in
advance by the study statistician, securely stored
electronically, and accessible only to intervention
staff. Research staff who enroll study participants
and collect outcome data will be unaware of the ran-
domization sequence and will be blinded to group
assignment.
Follow-up and Final Visits
Assessments given at baseline will be repeated four
times over the following 24 months (approximately
6, 12, 18, and 24 months).
The study does not plan to terminate anyone’s
participation early. They will continue in the study
if they develop dementia, for as long as they and
their legally authorized representative are willing to
continue. For those unable to attend follow-up evalu-
ations, we will offer a phone follow-up (CASI, survey
questions, adverse events [AEs]). If a participant asks
to withdraw, we will first ask them if we can contact
them again in a few months. If they are unwilling,
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we will ask permission to follow via medical records
only.
Intervention procedures
SMARRT intervention arm
The SMARRT intervention team includes behav-
ioral interventionists and a nurse care manager
supported by a SMARRT clinical support team that
includes a study physician and study psychologists.
After baseline assessments have been completed, the
intervention team will use a standardized procedure
to develop an individualized Alzheimer’s Risk Pro-
file for each participant randomized to the SMARRT
intervention arm. This will include a graphic dis-
play of the targeted risk factors showing areas where
the participant is doing well (green), areas where
they can continue to improve (orange), and areas
that are of particular risk for them (red). Participants
will then meet in-person with an interventionist to
review their risk profile and develop an initial person-
alized risk reduction action plan. Interventionists will
elicit participants’ values and motivators to reduce
Alzheimer’s risk and will use a decisional balance
process informed by motivational interviewing and
confidence ratings to help them choose 1–3 spe-
cific, achievable risk reduction steps that they are
most ready to adopt. Participants will be provided
with tools to track their progress. At each subsequent
visit, interventionists will review progress, problem-
solve barriers, and set new goals as needed. Following
detailed protocols, the intervention team will provide
counseling if participants experience distress related
to being informed of their Alzheimer’s risk.
The specific goals and approaches for each risk fac-
tor are listed in Table 3. Targeted areas will include:
increasing physical, mental, and social activities;
quitting smoking; healthy diet; controlling cardiovas-
cular risk factors (diabetes, hypertension), including
avoiding hypoglycemia in people with diabetes;
reducing depressive symptoms; improving sleep; and
decreasing use of potentially harmful medications.
Interventionists will provide patients with a menu
of options for each targeted risk factor, and goals
will be individualized to preferences, barriers, and
motivators to optimize intervention adherence. For
each target, there are options that leverage technology
as appropriate for the participants’ interest and skill
level. Non-technology based options are provided for
each target as well.
For management of medical conditions (e.g.,
hypertension, diabetes, depression, sleep disorders),
a “treat-to-target” approach will be used. This will
involve setting discrete goals for targeted conditions
(e.g., blood pressure, HbA1c, depressive symp-
toms) in consultation with the participant and the
primary care team, systematically monitoring partic-
ipant progress, making suggestions to the participant
and primary care team for adjusting treatment as
needed (treat-to-target) and supporting participant
self-care. Each week, the SMARRT intervention
team will meet with the SMARRT clinical sup-
port team for case reviews. Treatment algorithms
will be based on standard KPWA treatment rec-
ommendations synthesized from national guidelines.
Approval to exercise will be obtained from primary
care physicians (PCPs) to ensure participants can
safely engage in exercise prior to receiving inter-
ventions. Those who are approved and interested
will be encouraged to gradually increase their phys-
ical activity levels, focusing on walking. In addition,
our protocol includes strategies to reduce sitting
behavior as an alternative in those who are not inter-
ested or able to increase physical activity levels.
The SMARRT study physician or nurse will make
recommendations to the participant and their PCP
about management of targeted medical conditions
and use of specific high-risk medications via Epic
messaging, a secure, electronic, internal messaging
system that enables clinical staff to communicate
with each other about patient care. A detailed list
of contraindicated medications including generic and
brand names was developed using the 2015 updated
Beers criteria for potentially inappropriate medica-
tions in older adults [48] and a Kaiser reference for
high-risk medications in the elderly, focusing on med-
ications that impact cognitive function. Examples of
targeted medications include those with strong anti-
cholinergic properties, such as some antihistamines
(e.g., diphenhydramine), some antidepressants (e.g.,
amitriptyline, paroxetine), and sedative-hypnotics
(e.g., alprazolam, lorazepam). Nurses will work col-
laboratively with the primary care team to deprescribe
contraindicated medications, and health coaches will
work with participants on behavioral approaches to
manage underlying conditions such as depression or
insomnia. Prior studies have shown that simple edu-
cational interventions regarding risky medications
can substantially reduce usage in older patients [49].
Interventionists will follow a standard protocol for
delivering the SMARRT intervention that allows for
personalization of the specific risk reduction action
plan; these plans will evolve over time according to
participant progress, motivation and preferences or
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Table 3
Targeted risk factors, approaches and outcomes in SMARRT
Risk Factor Goal Menu of Options Tailored to Individual Preferences
& Abilities
Outcome Measures
Poorly controlled
hypertension
<140/90 (<130/90 in
patients with 10-year
atherosclerotic
cardiovascular disease
risk ≥10%)
Exercise, diet, medication changes using stepped
care “treat to target” approach with primary care
provider (PCP)
Blood pressure (study
visits; EHR)
Poorly controlled
diabetes
Hemoglobin A1c between
7 and 8
Exercise, diet, medication changes using stepped
care “treat to target” approach with primary care
HbA1c (EHR)
Physical inactivity Increase by 2500
steps/day OR maintain
if they are over 10,000
steps/day OR work up
to 8,000 steps per day
KPWA covered programs (e.g., Silver Sneakers,
EnhanceFitness), community programs (e.g.,
YMCA, mall walking), smart phone apps (e.g.,
Apple Health, MyFitnessPal, MapMyWalk),
wearable devices (e.g., pedometer, Fitbit),
protocol to reduce sitting
Rapid Assessment of
Physical Activity
(RAPA) for Older
Adults [35];
Actigraphy
Lack of mental
stimulation
Increase engagement in
cognitively stimulating
activities that are
enjoyable
Senior center activities, local college classes,
crossword puzzles and games, cognitive training
web programs, smart phone apps (e.g., Lumosity,
Brain HQ), on-line classes, volunteering;
mindfulness
Cognitive Activities
Questionnaire [37]
Social isolation Increase social
engagement
Senior center activities, group exercise, social
networking websites (e.g., Facebook), video chat
tools, volunteering
PROMIS – Satisfaction
with Participation in
Discretionary Social
Activities [36]
Depressive symptoms Fewer depressive
symptoms
Brief behavioral activation, Problem-solving
Treatment -Primary Care (PST-PC), referral to
behavioral health for cognitive behavioral therapy
(CBT), antidepressant medication via PCP, apps
based on CBT (e.g., MoodKit)
Center for Epidemiologic
Studies – Depression
Scale [40]
Sleep difficulty Improvement on
self-reported sleep
quality and sleep
duration
Sleep hygiene and sleep restriction education, CBT
for Insomnia (CBT-I), apps (e.g., Sleepio),
physical activity, behavioral activation
Pittsburgh Sleep Quality
Index [41]
Smoking Reduction/cessation Referral to Quit for Life, comprehensive program at
no cost to KPWA members delivered by phone,
web, or smart phone; mobile tools (NCI QuitPal)
Self-reported current
tobacco usage
Unhealthy diet Increase adherence to
MIND diet
Education about neuroprotective foods,
self-monitoring neuroprotective food intake with
food logs or websites/apps (e.g., Fitbit,
MyFitnessPal, MyPlate)
Mediterranean-DASH
Intervention for
Neurodegenerative
Delay (MIND) Diet
Score [38]
Contraindicated
Medications
Elimination/minimization Education on alternatives, including
nonpharmacologic therapy; study physician
contacts PCP with concerns and recommendations
Contra-indicated
medications for
cognition (2015 Beers
criteria [48] and KPWA
list)
newly identified risk factors. Staff will use a tracking
database to record information for each participant,
including date and time of session, identified risk fac-
tors, motivational barriers and important values, and
the outcome of discussions around developing goals.
For each participant, the exact number and mode
(phone or in-person) of contacts will differ, but we
will aim to have at least 1 contact per month with
each participant. Best practice will include in-person
meetings twice a year during the 2-year interven-
tion period. Even if a participant has relatively fewer
risk factors, or successfully addresses all of their risk
factors, interventionists will continue to check in with
them to ensure that they are maintaining their healthy
behaviors over time.
Health education (HE) control arm
In this pragmatic pilot trial, our goal is to com-
pare the personalized SMARRT intervention to what
is currently ‘usual care’ in the healthcare system,
while also providing enough interaction to main-
tain retention and blinding. Therefore, participants
randomized to the Health Education (HE) group
will receive mailed materials (typically 1-2 pages)
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every 3 months. This will include general infor-
mation on Alzheimer’s and dementia risk reduction
using materials from sources such as the Alzheimer’s
Association and educational materials commonly
provided as part of routine care at KPWA. The infor-
mation will address factors that will be targeted in the
SMARRT intervention, including physical, mental,
and social engagement; management of cardiovas-
cular risk factors; quitting smoking, healthy diet;
depression; sleep; and contraindicated medications.
HE participants will not be provided with personal-
ized information about their risk of Alzheimer’s and
dementia.
Adherence assessment
Interventionists will use the tracking database to
carefully document each contact with participants,
including the type (in person, phone) and outcome
(risk factor targeted, goal, whether the goal was met,
comments). This will enable us to determine the total
number and type of contacts per participant, the num-
ber and types of risk factors targeted, and the extent to
which goals were achieved. Interventionists also will
document weekly case review recommendations with
the clinical support team to supply information about
intervention adherence. In the control arm, there is
no active intervention (only passive materials, usual
care) so we cannot assess adherence or engagement.
Safety assessments
Data and Safety Monitoring Board (DSMB)
This study will be monitored by an external Data
and Safety Monitoring Board (DSMB), which will
act in an advisory capacity to the National Institute
on Aging (NIA) and the primary investigators (PIs)
to monitor participant safety, data quality, and the
progress of the study. Members of the DSMB are
listed in the Supplementary Material.
Adverse events (AEs) and serious adverse events
(SAEs)
We expect AEs associated with this intervention
to be minimal and consistent with risks of daily life
(e.g., anxiety caused by clinical assessments, muscle
aches from physical activity). AEs will be tracked
in the study database. We will use a multipronged
approach to collect information about AEs, includ-
ing active as well as passive modes. We will collect
information through: reports or contact with study
participants, surveys specifically asking about AEs,
and data in the EHR. All participants will be prompted
to report AEs and SAEs at their follow-up assess-
ment visits (approximately 6, 12, 18, and 24 months).
Those in the SMARRT group may also report AEs
during check-ins with interventionists. Those in the
HE group will be asked to respond to an AE form
sent in the mail every three months (approximately
months 3, 9, 15, and 21) when new health education
materials are sent. SAEs will be reported immedi-
ately to the project PIs and to the Institutional Review
Board (IRB) and DSMB. All interviewers, nurses,
and other study staff will be trained to identify poten-
tial AEs. These would include participant, family
member, or physician complaints; threats to withdraw
or actual withdrawals from the study; and responses
to questionnaire items indicating risk of serious con-
sequences.
Intervention discontinuation
Study participants may withdraw at any time for
any reason. Participants will continue to be followed,
with their permission, even if the study intervention
is discontinued. Follow-up measurement visits will
continue to be scheduled if the participant is willing.
If not, the study team will follow-up via by phone
calls and/or medical record review, as allowed by the
participant.
Statistical considerations
General design issues
The primary outcome will be a global cognitive
function composite score. To calculate the compos-
ite score, each raw test score will be standardized
based on the mean/standard deviation from all par-
ticipants at baseline. Then, the resulting z-scores will
be averaged across tests. Secondary outcomes will
include change in Alzheimer’s risk factors, individual
cognitive domain scores, physical performance, func-
tional ability, quality of life, and incidence of MCI
and dementia. Our hypotheses include the following:
1. We hypothesize that composite cognitive func-
tion scores among participants randomized
to the SMARRT intervention arm will show
improvement and/or less decline, relative to
those in the control arm.
2. We hypothesize that participants in the
SMARRT intervention will show improve-
ments on Alzheimer’s risk factors during the
intervention, relative to those in the control arm.
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3. We hypothesize that additional outcomes
including individual cognitive domain z-scores,
physical performance, functional ability, and
quality of life will be improved by the inter-
vention. We also hypothesize that incidence of
MCI and AD will be lower among participants
in the SMARRT arm.
Sample size
Because this is a pilot trial, our goal is to esti-
mate effect sizes for a larger trial. Therefore, sample
size estimates are based primarily on considerations
of precision rather than power and effect size. For
our primary outcome, our sample size of 200 will
enable us to estimate the effect size with a precision
of ± 0.08 SDs, assuming loss to follow-up of 10% and
intra-class correlation coefficient (ICC) of 0.6 based
on data from the FINGER trial [23]. This estimate
will be used in combination with a consensus clin-
ically meaningful effect, based on the literature and
investigator expertise. For secondary outcomes, we
estimate that precision will range from ± 0.06 SDs
to ± 0.08 SDs, depending on the ICC. We anticipate
that conversion to MCI/AD in this two-year trial will
be low (<10%); therefore, this outcome is considered
exploratory.
Data analyses
We will first assess balance on baseline character-
istics of the SMARRT and HE groups using graphical
and tabular checks for overlap, and statistical compar-
isons using t-tests, Wilcoxon, chi-square, and Fisher’s
exact tests as appropriate. All analyses will use intent-
to-treat principles.
To estimate the effect of SMARRT compared to
HE on our primary outcome, repeated measures of
the composite cognitive function score obtained at
0, 6, 12, 18, and 24 months, we will use a linear
mixed model (LMM), with fixed effects for the base-
line score, time, treatment, and the time-by-treatment
interaction, as well as random intercepts and slopes.
Exploratory analyses will be performed within the
intervention group to determine whether there is evi-
dence that the magnitude of the effect varies based
on the number or types of risk factors targeted, the
extent to which goals are achieved, or the number or
type of interventionist contacts. These analyses will
be restricted to the intervention group because among
controls, the number and type of risk factors targeted
will not be assessed, achievement of goals will be
undefined, and the number and type of contacts will
differ systematically by design. Hence these results
will be descriptive and will not estimate effect mod-
ification, mediation or dose-response, respectively.
We also will use multiple imputation to explore the
impact of missing data.
Similar methods will be used to assess the effect
of the intervention on changes in Alzheimer’s risk
factors over two years. Because this is a pilot study,
we chose not to pre-specify the benchmarks for
change/improvement for each risk factor. Instead,
we will quantify the amount of change achieved for
each risk factor. Generalized linear mixed models
(GLMMs), also with fixed effects for the baseline
value, time, treatment, and the time-by-treatment
interaction, and random intercepts and slopes, will
be used as appropriate to assess treatment effects on
binary, count, ordinal, and multinomial risk factors,
including the number of risk factors.
LMMs and GLMMs also will be used to com-
pare the impact of SMARRT versus HE on individual
cognitive domain z-scores, physical performance,
functional ability, and quality of life. Finally, Cox
proportional hazards models will be used to analyze
intervention effects on time to MCI and AD.
Data collection and quality assurance
Data collection forms
Outcome assessments will be performed by trained
research specialists who will be blinded to group
assignments. Most measures during the outcome
assessments will be collected using paper forms. The
data from these forms will be entered by the assessors
into a secure, web-based system overseen by UCSF.
Participants will complete questionnaires via a touch-
screen tablet computer. The participants’ responses
on those questionnaires will be automatically scored
and entered into the web-based database. Paper forms
will be available as back-ups if needed.
Data management
All data will be collected by KPWHRI staff in
KPWA facilities. Data will be collected and stored
separately for enrollment and intervention activities
and outcome assessments. Enrollment and inter-
vention data will be collected and stored within
KPWHRI. Outcome data will be entered into UCSF’s
secure web-based data entry site, called REDCap.
Quality assurance
Standardized training procedures will be imple-
mented for all study personnel and will be included
in a detailed Manual of Operating Procedures.
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Interventionists will have master’s degrees in relevant
health-related areas (e.g., public health, social work)
and will be trained by two licensed clinical psychol-
ogists to deliver motivational interviewing, problem
solving treatment, and general health coaching for all
health behaviors. They will be trained using didac-
tic techniques, role-play, and direct observation of
at least two initial sessions and two follow-up ses-
sions with corrective feedback. Outcome assessors
will be trained to administer the neuropsychological
test battery by the study neuropsychologist, who will
review audio recordings and data records of cognitive
test battery administration from at least two of the
first 10 assessment visits for quality assurance and
to provide corrective feedback. Similar procedures
will be used to train outcome assessors on secondary
outcome measures.
Data for a random sample of 10% of study partic-
ipants will be double-entered to determine the extent
of data entry error and adjust if indicated.
CONCLUSION
The Systematic Multi-domain Alzheimer’s Risk
Reduction Trial (SMARRT) will provide important
pilot data regarding the effects of a personal-
ized, Alzheimer’s risk reduction program delivered
through an integrated healthcare system. If our
hypotheses are supported, we plan to perform a larger
multi-site trial to determine whether the SMARRT
intervention can delay onset of MCI and AD in
high-risk older adults. Given the projected rise in
AD prevalence and the lack of disease-modifying
medications, it is critically important to test the effi-
cacy of pragmatic preventative interventions such
as SMARRT. If SMARRT proves to be effective in
this setting, it could be adapted and disseminated
to other health care delivery settings in other coun-
tries. Ultimately, multi-domain interventions such
as SMARRT have the potential to help address
the global burden of dementia by promoting brain-
healthy activities to reduce risk and delay onset of
AD and dementia.
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